| Name | Title | Contact Details |
|---|
TruSpine is a medical device company focused on entering the $10.2 billion (US) per annum spinal device market. The Company is developing uniquely disruptive technologies to revolutionise the spinal stabilisation market, commencing with three flagship pioneering, spinal devices. The Cervi-LOK™ (for the cervical and upper thoracic spine), GRASP Laminoplasty (a treatment for decompression of the spinal cord) & Faci-LOK™ (for the lumbar and lower thoracic spine). These unique devices represent a paradigm shift in spinal fixation, by providing exceptional stabilization while not altering the bony anatomy such as screws, staples or other devices which currently dominate the spinal market. The TruSpine philosophy and mantra is one of preserving nature`s design, and as such, the devices have been designed to be safer, faster and easier to implant. The potential cost savings to patients, insurers and surgeons can be significant. The technology is minimally intrusive, minimally invasive and reversable. The first product to market will be Cervi-LOK™, and will be the first posterior cervical stabilisation device in the world which fully preserves the boney anatomy of the spine. TruSpine has a phased product development strategy, and is planning to commence initial product marketing between late 2020 to early 2021. The overall aim is to establish the TruSpine products as the go-to solutions for the spinal stabilisation market. In addition to the three flagship platform products currently under development, the company also has a pipeline of additional and complementary spinal products.
MOBILion Systems is enabling advancements in disease diagnosis and treatment by commercializing instruments that improve multi-omics disease, drug, and biomarker discovery.
We`re committed to helping researchers and clinicians make a greater impact on science and health. For more than 25 years, our work has played an essential role in the cell research and cell therapy community. Our innovative tools support research at every level, from basic research to translational research to clinical application. Used by scientists and clinicians around the world, our integrated technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, cell culture, molecular analysis, and preclinical imaging. This complete portfolio enables the access, analysis, and utilization of primary and primary-derived cells. Our expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. Today, Miltenyi Biotec has more than 2,000 employees in 25 countries.
NexBio, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Farkas IRM is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.